OSE IMMUNO (OSE.PA) Fundamental Analysis & Valuation

EPA:OSE • FR0012127173

Current stock price

3.29 EUR
+0.02 (+0.55%)
Last:

This OSE.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OSE.PA Profitability Analysis

1.1 Basic Checks

  • In the past year OSE has reported negative net income.
  • In the past year OSE has reported a negative cash flow from operations.
  • OSE had negative earnings in 4 of the past 5 years.
  • In the past 5 years OSE reported 4 times negative operating cash flow.
OSE.PA Yearly Net Income VS EBIT VS OCF VS FCFOSE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

  • OSE's Return On Assets of -33.44% is in line compared to the rest of the industry. OSE outperforms 47.50% of its industry peers.
  • Looking at the Return On Equity, with a value of -68.84%, OSE is in line with its industry, outperforming 58.75% of the companies in the same industry.
Industry RankSector Rank
ROA -33.44%
ROE -68.84%
ROIC N/A
ROA(3y)-5.73%
ROA(5y)-10.16%
ROE(3y)-31.94%
ROE(5y)-31.6%
ROIC(3y)N/A
ROIC(5y)N/A
OSE.PA Yearly ROA, ROE, ROICOSE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for OSE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSE.PA Yearly Profit, Operating, Gross MarginsOSE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. OSE.PA Health Analysis

2.1 Basic Checks

  • OSE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OSE has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, OSE has more shares outstanding
  • The debt/assets ratio for OSE has been reduced compared to a year ago.
OSE.PA Yearly Shares OutstandingOSE.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OSE.PA Yearly Total Debt VS Total AssetsOSE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -0.27, we must say that OSE is in the distress zone and has some risk of bankruptcy.
  • OSE's Altman-Z score of -0.27 is in line compared to the rest of the industry. OSE outperforms 48.75% of its industry peers.
  • A Debt/Equity ratio of 0.64 indicates that OSE is somewhat dependend on debt financing.
  • OSE has a Debt to Equity ratio (0.64) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -0.27
ROIC/WACCN/A
WACC6.37%
OSE.PA Yearly LT Debt VS Equity VS FCFOSE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.86 indicates that OSE has no problem at all paying its short term obligations.
  • OSE has a better Current ratio (2.86) than 63.75% of its industry peers.
  • OSE has a Quick Ratio of 2.86. This indicates that OSE is financially healthy and has no problem in meeting its short term obligations.
  • OSE has a Quick ratio of 2.86. This is in the better half of the industry: OSE outperforms 66.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.86
OSE.PA Yearly Current Assets VS Current LiabilitesOSE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. OSE.PA Growth Analysis

3.1 Past

  • The earnings per share for OSE have decreased strongly by -191.65% in the last year.
  • The Revenue for OSE has decreased by -97.34% in the past year. This is quite bad
  • Measured over the past years, OSE shows a very strong growth in Revenue. The Revenue has been growing by 26.31% on average per year.
EPS 1Y (TTM)-191.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.08%
Revenue 1Y (TTM)-97.34%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%-98.36%

3.2 Future

  • The Earnings Per Share is expected to decrease by -34.36% on average over the next years. This is quite bad
  • OSE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.67% yearly.
EPS Next Y-117.49%
EPS Next 2Y-52%
EPS Next 3Y-34.36%
EPS Next 5YN/A
Revenue Next Year-46.75%
Revenue Next 2Y-38.39%
Revenue Next 3Y15.67%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
OSE.PA Yearly Revenue VS EstimatesOSE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
OSE.PA Yearly EPS VS EstimatesOSE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. OSE.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OSE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSE.PA Price Earnings VS Forward Price EarningsOSE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSE.PA Per share dataOSE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A cheap valuation may be justified as OSE's earnings are expected to decrease with -34.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52%
EPS Next 3Y-34.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OSE.PA Dividend Analysis

5.1 Amount

  • OSE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OSE.PA Fundamentals: All Metrics, Ratios and Statistics

OSE IMMUNO

EPA:OSE (4/2/2026, 7:00:00 PM)

3.29

+0.02 (+0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24
Earnings (Next)N/A
Inst Owners3.59%
Inst Owner ChangeN/A
Ins Owners25.4%
Ins Owner ChangeN/A
Market Cap73.89M
Revenue(TTM)2.22M
Net Income(TTM)-34.84M
Analysts82.5
Price Target15.16 (360.79%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1592.86%
EPS NY rev (3m)-1592.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.3
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 9.51
EV/EBITDA N/A
EPS(TTM)-1.59
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0.1
BVpS2.25
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.44%
ROE -68.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.73%
ROA(5y)-10.16%
ROE(3y)-31.94%
ROE(5y)-31.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.09%
Cap/Sales 3.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.86
Altman-Z -0.27
F-Score0
WACC6.37%
ROIC/WACCN/A
Cap/Depr(3y)5.62%
Cap/Depr(5y)12.68%
Cap/Sales(3y)4%
Cap/Sales(5y)3.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-191.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-130.08%
EPS Next Y-117.49%
EPS Next 2Y-52%
EPS Next 3Y-34.36%
EPS Next 5YN/A
Revenue 1Y (TTM)-97.34%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%-98.36%
Revenue Next Year-46.75%
Revenue Next 2Y-38.39%
Revenue Next 3Y15.67%
Revenue Next 5YN/A
EBIT growth 1Y-165.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-104.04%
EBIT Next 3Y-32.92%
EBIT Next 5YN/A
FCF growth 1Y-30.97%
FCF growth 3YN/A
FCF growth 5Y40.61%
OCF growth 1Y-31.28%
OCF growth 3YN/A
OCF growth 5Y39.6%

OSE IMMUNO / OSE.PA Fundamental Analysis FAQ

What is the fundamental rating for OSE stock?

ChartMill assigns a fundamental rating of 2 / 10 to OSE.PA.


What is the valuation status of OSE IMMUNO (OSE.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to OSE IMMUNO (OSE.PA). This can be considered as Overvalued.


How profitable is OSE IMMUNO (OSE.PA) stock?

OSE IMMUNO (OSE.PA) has a profitability rating of 1 / 10.


What is the financial health of OSE IMMUNO (OSE.PA) stock?

The financial health rating of OSE IMMUNO (OSE.PA) is 4 / 10.